These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 35264932)

  • 1. Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease.
    Wang M; Liu H; Ma Z
    Front Cell Neurosci; 2022; 16():832854. PubMed ID: 35264932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
    Han QW; Yuan YH; Chen NH
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endocannabinoid system as a target for the treatment of motor dysfunction.
    Fernández-Ruiz J
    Br J Pharmacol; 2009 Apr; 156(7):1029-40. PubMed ID: 19220290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.
    More SV; Choi DK
    Mol Neurodegener; 2015 Apr; 10():17. PubMed ID: 25888232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homeostatic changes of the endocannabinoid system in Parkinson's disease.
    Pisani V; Madeo G; Tassone A; Sciamanna G; Maccarrone M; Stanzione P; Pisani A
    Mov Disord; 2011 Feb; 26(2):216-22. PubMed ID: 21412829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson's Disease: A Perspective on Associated Therapeutic Interventions.
    Behl T; Kaur G; Bungau S; Jhanji R; Kumar A; Mehta V; Zengin G; Brata R; Hassan SSU; Fratila O
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid control of motor function at the basal ganglia.
    Fernández-Ruiz J; Gonzáles S
    Handb Exp Pharmacol; 2005; (168):479-507. PubMed ID: 16596785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocannabinoid system in Parkinson's disease.
    Di Filippo M; Picconi B; Tozzi A; Ghiglieri V; Rossi A; Calabresi P
    Curr Pharm Des; 2008; 14(23):2337-47. PubMed ID: 18781984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease.
    Navarrete F; García-Gutiérrez MS; Aracil-Fernández A; Lanciego JL; Manzanares J
    Neurotherapeutics; 2018 Apr; 15(2):459-469. PubMed ID: 29352424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
    Di Marzo V; Hill MP; Bisogno T; Crossman AR; Brotchie JM
    FASEB J; 2000 Jul; 14(10):1432-8. PubMed ID: 10877836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
    Palomo-Garo C; Gómez-Gálvez Y; García C; Fernández-Ruiz J
    Pharmacol Res; 2016 Aug; 110():181-192. PubMed ID: 27063942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
    García-Arencibia M; González S; de Lago E; Ramos JA; Mechoulam R; Fernández-Ruiz J
    Brain Res; 2007 Feb; 1134(1):162-70. PubMed ID: 17196181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [
    Ajalin RM; Al-Abdulrasul H; Tuisku JM; Hirvonen JES; Vahlberg T; Lahdenpohja S; Rinne JO; Brück AE
    Mov Disord; 2022 Aug; 37(8):1673-1682. PubMed ID: 35674270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids in Parkinson's Disease.
    Stampanoni Bassi M; Sancesario A; Morace R; Centonze D; Iezzi E
    Cannabis Cannabinoid Res; 2017; 2(1):21-29. PubMed ID: 28861502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease.
    Patricio F; Morales-Andrade AA; Patricio-Martínez A; Limón ID
    Front Pharmacol; 2020; 11():595635. PubMed ID: 33384602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of GPR55 and either cannabinoid CB
    Martínez-Pinilla E; Rico AJ; Rivas-Santisteban R; Lillo J; Roda E; Navarro G; Lanciego JL; Franco R
    Brain Struct Funct; 2020 Sep; 225(7):2153-2164. PubMed ID: 32691218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
    Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
    CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Cannabinoid Type 2 Receptors in Parkinson's Disease.
    Basile MS; Mazzon E
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary: Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease.
    Oikonomou P; Jost WH
    Front Cell Neurosci; 2022; 16():897930. PubMed ID: 35614972
    [No Abstract]   [Full Text] [Related]  

  • 20. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB
    Navarro G; Borroto-Escuela D; Angelats E; Etayo Í; Reyes-Resina I; Pulido-Salgado M; Rodríguez-Pérez AI; Canela EI; Saura J; Lanciego JL; Labandeira-García JL; Saura CA; Fuxe K; Franco R
    Brain Behav Immun; 2018 Jan; 67():139-151. PubMed ID: 28843453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.